RETRACTED: Potamogeton perfoliatus L. Extract Attenuates Neuroinflammation and Neuropathic Pain in Sciatic Nerve Chronic Constriction Injury-Induced Peripheral Neuropathy in Rats
A Retraction of the Original Research article
Potamogeton perfoliatus L. extract attenuates neuroinflammation and neuropathic pain in sciatic nerve chronic constriction injury-induced peripheral neuropathy in rats
by Mahmoud MF, Rezq S, Alsemeh AE, Abdelfattah MAO, El-Shazly AM, Daoud R, El Raey MA and Sobeh M (2021). Front. Pharmacol. 12:799444. doi: 10.3389/fphar.2021.799444
The Journal retracts the 20 December 2021 article cited above.
Following publication, concerns were raised regarding the integrity of the images in the published figures 4 and 7. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.
This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors have agreed to this retraction.
Citation: Frontiers Editorial Office (2024) Retraction: Potamogeton perfoliatus L. extract attenuates neuroinflammation and neuropathic pain in sciatic nerve chronic constriction injury-induced peripheral neuropathy in rats. Front. Pharmacol. 15:1515818. doi: 10.3389/fphar.2024.1515818
Received: 23 October 2024; Accepted: 23 October 2024;
Published: 28 October 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org